Superiority of delayed risk stratification in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation

Nuclear Medicine Communications

Volumn 35, Issue 11, 2014, Pages 1119-1126

  Hong, Chae Moon ^a   Lee, Won Kee ^a   Jeong, Shin Young ^a   Lee, Sang Woo ^a   Ahn, Byeong Cheol ^a   Lee, Jaetae ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

Risk management; Structural progression; Survival; Thyroid neoplasm

Indexed keywords

IODINE 131; LEVOTHYROXINE; LIOTHYRONINE; RADIOACTIVE IODINE; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN;

ADULT; AMERICAN THYROID ASSOCIATION RISK STRATIFICATION; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; DELAYED RISK STRATIFICATION; DIFFERENTIATED THYROID CANCER; DISEASE COURSE; FEMALE; FOLLOW UP; GAMMA CAMERA; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; THYROIDECTOMY; TREATMENT RESPONSE; TUMOR ABLATION; ABLATION THERAPY; BIOASSAY; DISEASE FREE SURVIVAL; MIDDLE AGED; PATHOLOGY; PROCEDURES; THYROID NEOPLASMS; TREATMENT OUTCOME;

ABLATION TECHNIQUES; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RISK ASSESSMENT; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 84916217831     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0000000000000183     Document Type: Article

References (22)

1. Wong RM, Bresee C, Braunstein GD. Comparison with published systems of a new staging system for papillary and follicular thyroid carcinoma. Thyroid 2013; 23:566-574.
2. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167-1214.
3. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
4. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154:787-803.
5. Hong CM, Ahn BC, Park JY, Jeong SY, Lee SW, Lee J. Prognostic implications of microscopic involvement of surgical resection margin in patients with differentiated papillary thyroid cancer after high-dose radioactive iodine ablation. Ann Nucl Med 2012; 26:311-318.
6. Tuttle RM, Leboeuf R, Shaha AR. Medical management of thyroid cancer: a risk adapted approach. J Surg Oncol 2008; 97:712-716.
7. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010; 20:1341-1349.
8. Vaisman F, Tala H, Grewal R, Tuttle RM. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. Thyroid 2011; 21:1317-1322.
9. Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, Pacini F. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 2011; 165:441-446.
10. Vaisman F, Shaha A, Fish S, Michael Tuttle R. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol (Oxf) 2011; 75:112-119.
11. Paeng JC, Kang KW, Park do J, Oh SW, Chung JK. Alternative medical treatment for radioiodine-refractory thyroid cancers. Nucl Med Mol Imaging 2011; 45:241-247.
12. Seo JH, Lee SW, Ahn BC, Lee J. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT. Clin Endocrinol (Oxf) 2010; 72:558-563.
13. Hong CM, Ahn BC, Jeong SY, Lee SW, Lee J. Distant metastatic lesions in patients with differentiated thyroid carcinoma. Clinical implications of radioiodine and FDG uptake. Nuklearmedizin 2013; 52:121-129.
14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
15. Agresti A. An introduction to categorical data analysis. Hoboken, New Jersey: Wiley; 2007.
16. Valle LA, Baskin RLG, Porter K, Sipos JA, Khawaja R, Ringel MD, et al. In thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30 mu U/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin. Thyroid 2013; 23: 185-193.
17. Castagna MG, Tala Jury HP, Cipri C, Belardini V, Fioravanti C, Pasqui L, et al. The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma. J Endocrinol Invest 2011; 34:e219-e223.
18. Yim JH, Kim EY, Bae Kim W, Kim WG, Kim TY, Ryu JS, et al. Long-term consequence of elevated thyroglobulin in differentiated thyroid cancer. Thyroid 2013; 23:58-63.
19. Spencer C, Fatemi S, Singer P, Nicoloff J, Lopresti J. Serum basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid 2010; 20:587-595.
20. Iervasi A, Iervasi G, Ferdeghini M, Solimeo C, Bottoni A, Rossi L, et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf) 2007; 67:434-441.
21. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Tumeurs de la Thyroïde Refractaires Network for the Essai Stimulation Ablation Equivalence Trial. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med 2012; 366:1663-1673.
22. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 2012; 366:1674-1685.